MoonLake Immunotherapeutics (MLTX)
Nasdaq: MLTX · Pharmaceutical Preparations · Zug, CH · filing with the SEC since 2020
Who owns MoonLake Immunotherapeutics
As filed with the SECHolders of 5% or more
3
Bvf Partners L P/il holds 19.7% of Class A ordinary share, par value $0.0001 per share, as its SCHEDULE 13D/A filed Jun 29, 2026 says.
Directors and officers
18
report now, of 25 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Bvf Partners L P/il
SCHEDULE 13D/A · filed Jun 29, 2026 · Class A ordinary share, par value $0.0001 per share · 22.3% in Apr 2, 2026
Deep Track Capital, LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Class A ordinary share, par value $0.0001 per share · 6.46% in Nov 12, 2025
T. Rowe Price Investment Management, Inc.
SCHEDULE 13G · filed Aug 14, 2026 · COMMON STOCK
T. Rowe Price Associates, Inc.
SCHEDULE 13G/A · filed May 14, 2025 · COMMON STOCK · reported falling below 5%, from 5.3% in Feb 14, 2025
Cormorant Asset Management, LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Class A ordinary share, par value $0.0001 per share · reported falling below 5%, from 6.25% in May 15, 2026
Avoro Capital Advisors LLC
SCHEDULE 13G/A · filed Nov 14, 2025 · Class A Ordinary Shares, par value $0.0001 per share · reported falling below 5%, from 6.5% in Aug 14, 2025
Chen Bihua
SCHEDULE 13G/A · filed Oct 1, 2025 · Class A Ordinary Shares · reported falling below 5%
Fmr LLC
SCHEDULE 13G/A · filed Nov 5, 2025 · CLASS A COMMON STOCK · reported falling below 5%, from 9% in Aug 6, 2025
What MLTX reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
MoonLake AG
An entity · legal entity · owns, named in the 10-K filed Feb 25, 2026
Insider tradesForm 4
27sales
1purchases
18sales on a scheduled plan
4people selling
$83.0Msold, in dollars
$100,000bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window5 of 30 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Lampert Mark N | director | 3 | $63.0M | 0 | 0 | $0 |
| Santos Da Silva Jorge | Chief Executive Officer | 7 | $8.7M | 3 | 0 | $0 |
| Reich Kristian | Chief Scientific Officer | 10 | $8.1M | 8 | 0 | $0 |
| Bodenstedt Matthias | Chief Financial Officer | 7 | $3.2M | 7 | 1 | $100,000 |
| Cormorant Global Healthcare Master Fund, LP | 10% owner | 1 | $0 | 0 | 0 | $0 |